Breaking News

Incannex Appoints Quest Pharmaceutical Services to Advance Nicotine, Opioid Products

To provide regulatory advice and manage clinical trials for the development of CannQuit and ReneCann products for addiction and immune-disordered skin diseases.

Incannex Healthcare Ltd., a pharmaceutical company developing medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet medical needs, has appointed Quest Pharmaceutical Services (QPS) to provide regulatory advice and manage clinical trials for the development of CannQuit and ReneCann products for addiction and immune-disordered skin diseases. CEO and managing director, Joel Latham said, “QPS is a perfect fit for us to develop these products across the globe. Not only ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters